GlassScriptPhysician profile
Kevin L Schaffer
NPI 1104872084
$12,505.92
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,547 · 2020: $1,115 · 2021: $2,246 · 2022: $1,091 · 2023: $1,258 · 2024: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,506.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $5,572.12 | 2019-2023 | |
| Biocryst US Sales Co., LLC | $1,259.56 | 2021-2023 | Orladeyo |
| Astrazeneca Pharmaceuticals LP | $1,194.37 | 2019-2024 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $527.58 | 2019-2024 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $432.89 | 2019-2023 | |
| Pfizer INC. | $424.16 | 2019-2023 | |
| Pharming Healthcare, INC. | $373.87 | 2019-2024 | Ruconest |
| Octapharma USA, INC. | $365.27 | 2020-2024 | Cutaquig |
| Takeda Pharmaceuticals U.S.A., INC. | $363.11 | 2020-2024 | Takhzyro, Fruzaqla |
| Csl Behring | $325.96 | 2019-2024 | Haegarda, Hizentra |
| Kaleo, INC. | $272.87 | 2019-2023 | Auvi-Q |
| Grifols USA, LLC | $266.68 | 2019-2024 | Xembify |
| Sanofi-Aventis U.S. LLC | $225.53 | 2021 | |
| Optinose US, INC. | $144.83 | 2020-2024 | |
| Amgen INC. | $131.87 | 2022-2024 | Tezspire |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $129.15 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $113.41 | 2019-2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.49 | 2021 | |
| Shire North American Group INC | $69.22 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $62.93 | 2020-2021 | |
| Blueprint Medicines Corporation | $47.31 | 2023 | Ayvakit |
| Merck Sharp & Dohme LLC | $37.31 | 2022-2023 | |
| Abbvie INC. | $34.48 | 2022 | |
| Leo Pharma INC. | $21.33 | 2023 | Adbry |
| Biocryst Pharmaceuticals, INC. | $18.73 | 2020 | |
| Alk-Abello, INC | $16.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Schaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.